Ceftriaxone Dosing in a Critically Ill Patient With Hypoalbuminemia During Continuous Venous Hemofiltration: Emphasis on Unbound Pharmacokinetics

J Clin Pharmacol. 2020 Jan;60(1):140-142. doi: 10.1002/jcph.1503. Epub 2019 Aug 13.

Authors

Renée M F Ebisch¹, Sjoerd D Meenks^{2

3}, Norbert Foudraine¹, Paddy K C Janssen^{2

3}, Jos L M L le Noble^{1

4}

Affiliations

¹ Department of Intensive Care, VieCuri Medical Center Venlo, Venlo, the Netherlands.
² Department of Hospital Pharmacy, VieCuri Medical Center Venlo, Venlo, the Netherlands.
³ Department of Clinical Pharmacy and Toxicology, CAPHRI School of Public Health and Primary Care, Maastricht University Medical Center, Maastricht, the Netherlands.
⁴ Department of Pharmacology and Toxicology, Maastricht University, Maastricht, the Netherlands.

PMID: 31407809
DOI: 10.1002/jcph.1503

No abstract available

Keywords: ceftriaxone; continuous venovenous hemofiltration; hypoalbuminemia; pharmacokinetics; unbound plasma concentration.

Publication types

Case Reports
Letter

MeSH terms

Aged
Anti-Bacterial Agents / pharmacokinetics*
Anti-Bacterial Agents / therapeutic use
Ceftriaxone / pharmacokinetics*
Ceftriaxone / therapeutic use
Critical Illness
Escherichia coli Infections / complications
Escherichia coli Infections / drug therapy*
Escherichia coli Infections / metabolism
Female
Hemofiltration
Humans
Hypoalbuminemia / complications*
Shock, Septic / complications
Shock, Septic / therapy*

Substances

Anti-Bacterial Agents
Ceftriaxone